|
|
Phase II Study of Paclitaxel Poliglumex and Transdermal Estradiol in Patients With Androgen-Independent Stage IV Prostate Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Temporarily closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
OHSU-2656 SOL-06048-L, NCT00459810
|
|
|
Objectives Primary - Determine the PSA response rate in patients with androgen independent metastatic prostate cancer treated with paclitaxel poliglumex and transdermal estradiol.
Secondary - Determine the toxicity of this regimen in these patients.
- Determine the response rate in patients treated with this regimen.
- Determine the time to PSA progression and measurable disease progression in patients treated with this regimen.
- Determine time to death from all causes
in patients treated with this regimen.
- Correlate levels of serum estradiol, serum cathepsin B, and bone turnover markers with PSA response in patients treated with this regimen.
Entry Criteria Disease Characteristics:
Prior/Concurrent Therapy:
-
See Disease Characteristics
- At least 6 weeks since prior antiandrogen therapy (4 weeks for flutamide)
- No current evidence of an antiandrogen withdrawal response
- More than 4 weeks since prior radiotherapy
- More than 8 weeks since prior radiopharmaceutical therapy (strontium chloride Sr 89, samarium Sm 153 lexidronam pentasodium)
- No prior paclitaxel
- No other concurrent cytotoxic agents
- No other concurrent chemotherapy or biologic response modifiers
- No concurrent supplements known or suspected to contain supplemental estrogens
Patient Characteristics:
- ECOG performance status 0-2
- Life expectancy > 3 months
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Creatinine ≤ 1.5 times upper limit of normal (ULN)
- Bilirubin ≤ 1.5 times ULN
- AST and ALT ≤ 2.5 times ULN
- No other active malignancy except adequately treated nonmelanoma skin cancer or other noninvasive or in situ neoplasm
- No other significant active medical illness or infection that would preclude study compliance
- No significant cardiovascular illness, including any of the following:
- NYHA class III or IV congestive heart failure
- Unstable angina
- Myocardial infarction within the past 6 months
- Acute deep venous thrombosis
- Acute pulmonary embolism
- No significant peripheral neuropathy ≥ grade 2
Expected Enrollment 50A total of 50 patients will be accrued for this study. Outcomes Primary Outcome(s)PSA response rate
Secondary Outcome(s)Toxicity Response rate Time to PSA progression and measurable disease progression Time to death Correlation of levels of serum estradiol, serum cathepsin B, and bone turnover markers with PSA response
Outline This is a multicenter study. Patients receive transdermal estradiol continuously (patches changed every 7 days) until the PSA level rises. Patients whose PSA increases above baseline or PSA decreases < 10% after 4 weeks of estradiol therapy or whose serum PSA reduction is < 50% after 12 weeks of estradiol therapy also receive paclitaxel poliglumex therapy. These patients receive paclitaxel poliglumex IV over 10-20 minutes on day 1. Treatment with paclitaxel poliglumex repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed every 6 months.
Trial Contact Information
Trial Lead Organizations Oregon Health and Science University Cancer Institute | | | Tomasz Beer, MD, Principal investigator | | Ph: 503-494-3253; 800-494-1234 |
| |
Registry Information | | Official Title | | A Phase II Study of Paclitaxel Poliglumex (PPX) in Combination with Transdermal Estradiol for the Treatment of Androgen Independent Prostate Cancer After Docetaxel Chemotherapy | | Trial Start Date | | 2007-02-28 | | Trial Completion Date | | 2010-02-28 (estimated) | | Registered in ClinicalTrials.gov | | NCT00459810 | | Date Submitted to PDQ | | 2007-03-09 | | Information Last Verified | | 2008-08-26 | | NCI Grant/Contract Number | | CA69533 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|